Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 22 results for "praful bohra"

Enter Natco Pharma at around Rs 700: Praful Bohra
Money Control

Don’t see any fundamental movement in Ranbaxy, Wockhardt: Pr...

You take Wockhardt, Ranbaxy, Strides Arcolab, all these companies, all these names have sort of a problem with the FDA. In an interview with ET Now, Praful Bohra, Sr Research Analyst, Pharma, Nirmal Bang, shares his outlook for some pharma stocks. Excerpts: ... Economic Times, 2 weeks ago

1 images for "praful bohra"

Moneycontrol.com, 2 weeks ago

US approvals key to Glenmark's prospects

Operations here and in other countries continue to fare well; earnings growth to pick up in FY15 as new US product launches gain momentum Ujjval Jauhari | Mumbai April 9, 2014 Last Updated at 21:42 IST Glenmark Pharmaceuticals has seen an increase ...
 Business Standard India1 week ago US approvals hold key to Glenmark's prospects  Business Standard India1 week ago
Moneycontrol.com

Natco Pharma up 5%, US PTO rejects Teva's application

Shares of Natco Pharma ended 5 percent higher after US patent office rejected Teva's patent reissue application on Copaxone. This, however, does not change the US Supreme Court hearing but makes a stronger case for Natco and Mylan. In its ruling, ...
 Moneycontrol.com1 week ago

Natco's launch of Copaxone in May 'at risk': Nirmal Bang

W However, there is a likelihood of Natco Phrama going in for an at risk launch around May after all the necessary approvals are received, he said. Teva is the innovator of the multiple sclerosis drug Copaxone . SC ruling in favour of Teva may ...
 Moneycontrol.com2 weeks ago Natco’s launch of Copaxone in May 'at risk': Nirmal Bang  Money Control2 weeks ago
NDTV Profit

Sensex, Nifty end at record high

03.40 p.m. Markets end at record high. Sensex closes at 22,214, up 119 points, Nifty ends at 6,642 after rising 40 points. State-run lenders emerged as the biggest gainers and pharma stocks were the top underperformers. SBI and PNB gained on broker ...
 NDTV Profit2 weeks ago Share market live: Nifty struggles near 6,650; SBI soars  NDTV Profit3 weeks ago Share market live: Nifty edges above 6,650 to record high  NDTV3 weeks ago

Should you sell pharma stocks in your portfolio?

Pharma stocks are on track for a fourth straight losing session on Thursday. The BSE healthcare index, which comprises of well-known drugmakers, traded 0.7 per cent lower as of 12.50 p.m., underperforming the broader Sensex, which gained 0.5 per ...
 NDTV Profit3 weeks ago

US generics benefit from pharma see-saw

The rising regulatory hurdles for Indian pharmaceutical companies in the US could prove a blessing for American generic medicine manufacturers. While leading Indian drug makers are inreasingly facing enforcement action as well as reputational ...
 Smart Investor3 weeks ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - praful bohra
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less